The incidence of APS-events in the control group (0.62% per year) was practically the same as was described in the healthy Caucasian population (0.65% per year).[16] Moreover, the incidence of APS-events in the previously asymptomatic IgA-aB2GP1 carriers was 3.1% per year, which was similar to 3.18% per year described for untreated asymptomatic aPL-consensus carriers without any prophylactic treatment[27] and is also within the reported range (1.36–3.8%) described in previous studies assessing the risk of events in asymptomatic aPL-consensus carriers. This evidence concerns the gene CD79A and autoimmune polyendocrinopathy.